Drug Type Antibody drug conjugate (ADC) |
Synonyms Recombinant Humanized Anti-Human Epidermal Growth Factor Receptor Monoclonal Antibody and the Dolastatins Derivative DUO5 Conjugated |
Target |
Action antagonists, inhibitors |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tubulin inhibitors, ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC11H22N4O4 |
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N |
CAS Registry159858-33-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | China | 17 Dec 2021 | |
HER2 Positive Solid Tumors | Phase 1 | China | 17 Dec 2021 | |
HER2 Positive Solid Tumors | Phase 1 | China | 17 Dec 2021 | |
HER2 Positive Solid Tumors | Phase 1 | China | 17 Dec 2021 |
Phase 1 | HER2 Positive Solid Tumors HER2 positive | 15 | (qbbfxtbfqk) = sofltcuxsh zcfaqjutyl (gpvouupbdz ) View more | Positive | 21 Oct 2023 |